Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 5, p. 524–529, 2021. DOI: 10.25251/skin.5.5.10. Disponível em: https://skin.dermsquared.com/skin/article/view/1309. Acesso em: 18 may. 2025.